Q2 FY2026 · ended Jun 30, 2026 · Revenue $17.84M, +18.9% YoY · Filed Aug 12, 2026
Journey Medical Corp (DERM) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $17.8 million and a net loss of $312,000. As of Jun 30, 2026 it held $25.6 million in cash and investments and $25.5 million in total debt.
Revenue
$17.84M
+18.9% vs year-ago quarter
Net income
$-312,000
+91.8% vs year-ago quarter
Operating cash flow
$-1.73M
-84.1% vs year-ago quarter
Free cash flow
—
EPS
$-0.01
+93.8% vs year-ago quarter
Dividend per share
None
Shares outstanding
11.56M
+2.1% vs prior quarter
Net cash
$102,000
Q2 FY2026
Operating margin
-4.5%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DERM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Scottsdale, AZ
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1867066
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $17.8M | $15.9M | $16.1M | $17.0M | $15.0M |
| Operating income | $456,000 | -$1.5M | -$443,000 | -$1.5M | -$2.9M |
| Net income | -$312,000 | -$2.2M | -$1.2M | -$2.3M | -$3.8M |
| Diluted EPS | -$0.01 | -$0.08 | -$0.05 | -$0.09 | -$0.16 |
| Operating cash flow | -$1.7M | $2.9M | -$6.3M | -$2.4M | -$942,000 |
| Total assets | $98.4M | $91.5M | $94.6M | $85.2M | $81.2M |
| Total liabilities | $66.2M | $60.7M | $62.7M | $59.3M | $61.9M |
| Stockholders' equity | $32.1M | $30.8M | $31.9M | $25.9M | $19.2M |
| Cash and investments | $25.6M | $27.2M | $24.1M | $24.9M | $20.3M |
| Total debt | $25.5M | $25.5M | $25.4M | $25.3M | $25.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 26, 2026 | Jun 24, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | May 13, 2026 |
| 8-K |
Current report
Other events
|
Apr 21, 2026 | Apr 21, 2026 |
All 229 Journey Medical Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.